In last trading session, Praxis Precision Medicines Inc (NASDAQ:PRAX) saw 0.39 million shares changing hands with its beta currently measuring 2.62. Company’s recent per share price level of $53.85 trading at -$1.09 or -1.98% at ring of the bell on the day assigns it a market valuation of $1.10B. That closing price of PRAX’s stock is at a discount of -70.53% from its 52-week high price of $91.83 and is indicating a premium of 50.42% from its 52-week low price of $26.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.38 million shares which gives us an average trading volume of 345.05K if we extend that period to 3-months.
For Praxis Precision Medicines Inc (PRAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.42. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -3.3 in the current quarter.
Praxis Precision Medicines Inc (NASDAQ:PRAX) trade information
Praxis Precision Medicines Inc’s shares saw a change of 1.37% in year-to-date performance and have moved 6.55% in past 5-day. Praxis Precision Medicines Inc (NASDAQ:PRAX) showed a performance of 23.91% in past 30-days. Number of shares sold short was 1.74 million shares which calculate 5.78 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 85 to the stock, which implies a rise of 36.65% to its current value. Analysts have been projecting 73 as a low price target for the stock while placing it at a high target of 120. It follows that stock’s current price would drop -35.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -35.56% for stock’s current value.
Praxis Precision Medicines Inc (PRAX) estimates and forecasts
This year revenue growth is estimated to fall -91.91% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 157.13k for the same. And 12 analysts are in estimates of company making revenue of 152.68k in the next quarter. Company posted 357k and 302k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 8.54% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -25.17% while estimates for its earnings growth in next 5 years are of -4.40%.
Praxis Precision Medicines Inc (NASDAQ:PRAX)’s Major holders
Insiders are in possession of 0.16% of company’s total shares while institution are holding 122.02 percent of that, with stock having share float percentage of 122.21%. Investors also watch the number of corporate investors in a company very closely, which is 122.02% institutions for Praxis Precision Medicines Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at PRAX for having 1.29 million shares of worth $53.52 million. And as of 2024-06-30, it was holding 6.874 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 1.24 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.5638 of outstanding shares, having a total worth of $51.1 million.
On the other hand, SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025, the former fund manager was holding 748.24 shares of worth $40.29 million or 3.67% of the total outstanding shares. The later fund manager was in possession of 562.19 shares on Mar 31, 2025, making its stake of worth around $30.27 million in the company or a holder of 2.76% of company’s stock.
